search
Back to results

DORAYA-HF OUS Assessment of the Doraya Catheter for the Treatment of ADHF Patients With Insufficient Response to Diuretics

Primary Purpose

Acute Decompensated Heart Failure

Status
Not yet recruiting
Phase
Not Applicable
Locations
Georgia
Study Type
Interventional
Intervention
Doraya catheter
Sponsored by
Revamp Medical Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Decompensated Heart Failure focused on measuring ADHF

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Subject is hospitalized with primary diagnosis of ADHF. N-terminal-pro-brain natriuretic peptide (NT-proBNP) ≥1,000 pg/m orvBNP≥250 pg/mL. Evidence of fluid overload. Subject insufficiently responds to IV diuretic therapy Exclusion Criteria: Systolic blood pressure < 80 mmHg at the time of screening. 2. Acute myocardial infarction or acute coronary syndrome or cardiogenic shock or pleurocentesis within past 14 days or cardiovascular intervention within past 14 days. 3. Complex congenital heart disease (e.g., Tetralogy of Fallot subjects, single ventricle physiology). 4. Known active myocarditis, hypertrophic obstructive cardiomyopathy, infiltrative cardiomyopathy (e.g., amyloidosis), constrictive pericarditis or cardiac tamponade. 5. Severe Aortic valvular disorder (i.e., hemodynamically relevant valvular diseases such as severe stenosis \severe regurgitation) or Severe mitral disease with planned intervention. 6. Evidence of active systemic infection documented by either one of the following: fever >38°C/100°F, or ongoing uncontrolled infection (i.e., inflammatory parameters not decreasing despite > 48 hours of antibiotic treatment). 7. Moribund subject or subject with severe or deteriorating damage in more than 3 critical body systems, based on investigator's clinical judgement.

Sites / Locations

  • LLC "Aleksandre Aladashvili clinic"
  • LLC "American Hospital Network"
  • LLC Bokhua Memorial Cardiovascular Center
  • LTD Israel Georgian Medical Research Clinic Helsicore

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ADHF patients

Arm Description

ADHF patients with insufficient response to diuretics treated with the Doraya catheter

Outcomes

Primary Outcome Measures

Serious Adverse Events
Device or procedure related SAEs rate (including MACE) based on MM adjudication.
Urine Output
Change in total urine output

Secondary Outcome Measures

Full Information

First Posted
May 16, 2023
Last Updated
October 9, 2023
Sponsor
Revamp Medical Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05876078
Brief Title
DORAYA-HF OUS Assessment of the Doraya Catheter for the Treatment of ADHF Patients With Insufficient Response to Diuretics
Official Title
DORAYA-HF EU: Assessment of the Doraya Catheter for the Treatment of Volume Overload in Acute Heart Failure Patients With Insufficient Response to Diuretics
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 1, 2024 (Anticipated)
Primary Completion Date
January 30, 2025 (Anticipated)
Study Completion Date
April 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Revamp Medical Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes

5. Study Description

Brief Summary
The study objective is to evaluate the feasibility of the Doraya Catheter and measure clinical performance and safety endpoints, in ADHF patients deemed to have insufficient diuretic response.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Decompensated Heart Failure
Keywords
ADHF

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
35 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ADHF patients
Arm Type
Experimental
Arm Description
ADHF patients with insufficient response to diuretics treated with the Doraya catheter
Intervention Type
Device
Intervention Name(s)
Doraya catheter
Intervention Description
Temporary deployment of the Doraya catheter in ADHF patients
Primary Outcome Measure Information:
Title
Serious Adverse Events
Description
Device or procedure related SAEs rate (including MACE) based on MM adjudication.
Time Frame
30 day post Doraya procedure
Title
Urine Output
Description
Change in total urine output
Time Frame
24 hours pre Doraya deployment, during Doraya indwelling period, and for 24 hours after Doraya removal

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is hospitalized with primary diagnosis of ADHF. N-terminal-pro-brain natriuretic peptide (NT-proBNP) ≥1,000 pg/m orvBNP≥250 pg/mL. Evidence of fluid overload. Subject insufficiently responds to IV diuretic therapy Exclusion Criteria: Systolic blood pressure < 80 mmHg at the time of screening. 2. Acute myocardial infarction or acute coronary syndrome or cardiogenic shock or pleurocentesis within past 14 days or cardiovascular intervention within past 14 days. 3. Complex congenital heart disease (e.g., Tetralogy of Fallot subjects, single ventricle physiology). 4. Known active myocarditis, hypertrophic obstructive cardiomyopathy, infiltrative cardiomyopathy (e.g., amyloidosis), constrictive pericarditis or cardiac tamponade. 5. Severe Aortic valvular disorder (i.e., hemodynamically relevant valvular diseases such as severe stenosis \severe regurgitation) or Severe mitral disease with planned intervention. 6. Evidence of active systemic infection documented by either one of the following: fever >38°C/100°F, or ongoing uncontrolled infection (i.e., inflammatory parameters not decreasing despite > 48 hours of antibiotic treatment). 7. Moribund subject or subject with severe or deteriorating damage in more than 3 critical body systems, based on investigator's clinical judgement.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sahar Boostenay
Phone
+972544621243
Email
Saharb@revampmedical.com
First Name & Middle Initial & Last Name or Official Title & Degree
Yael Shohat
Phone
+972526384749
Email
Yaels@revampmedical.com
Facility Information:
Facility Name
LLC "Aleksandre Aladashvili clinic"
City
Tbilisi
Country
Georgia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shalva Petriashvili, M.D.
Facility Name
LLC "American Hospital Network"
City
Tbilisi
Country
Georgia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zviad Kipiani, M.D.
Facility Name
LLC Bokhua Memorial Cardiovascular Center
City
Tbilisi
Country
Georgia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vakhtang Kipiani, M.D.
Facility Name
LTD Israel Georgian Medical Research Clinic Helsicore
City
Tbilisi
Country
Georgia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Irakli Gogorishvili, M.D.

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

DORAYA-HF OUS Assessment of the Doraya Catheter for the Treatment of ADHF Patients With Insufficient Response to Diuretics

We'll reach out to this number within 24 hrs